The promising results of the randomized, double-blind, placebo-controlled, phase III trial REACH-2 led to the FDA approval of ramucirumab as a single agent for HCC in patients with AFP levels ≥ 400 ng/mL and previously treated with sorafenib [41]. The gene discussed is AFP; the disease is hepatocellular carcinoma.